Brian Gliniak
Amgen (United States)(US)
Publications by Year
Research Areas
Cell death mechanisms and regulation, Virus-based gene therapy research, T-cell and B-cell Immunology, Glycosylation and Glycoproteins Research, Immune Cell Function and Interaction
Most-Cited Works
- → Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo(1999)2,493 cited
- → Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.(1994)1,558 cited
- → Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions(2001)693 cited
- → Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death(1995)589 cited
- → Molecular cloning of a ligand for the flt3flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells(1993)541 cited
- → CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF(1993)537 cited
- → Cloning of the Murine Thymic Stromal Lymphopoietin (Tslp) Receptor(2000)414 cited
- Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.(1999)
- → Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice(2002)173 cited
- → 4-1BB-Specific Monoclonal Antibody Promotes the Generation of Tumor-Specific Immune Responses by Direct Activation of CD8 T Cells in a CD40-Dependent Manner(2002)135 cited